Clinical Trial

Association Between LRG and Histologic Remission in Ulcerative Colitis

Recruiting
View on ClinicalTrials.gov →
Summary
We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed annually, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-15; most recent amendment 2026-04-21.
Trial Details
NCT Number NCT06372613
Lead Sponsor Showa Inan General Hospital
Conditions Ulcerative Colitis in Histologic Remission
Enrollment 100 participants
Start Date 2024-02-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13